- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 527607, 8 pages
Prostaglandins as PPAR Modulators in Adipogenesis
Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
Received 29 September 2012; Accepted 20 November 2012
Academic Editor: Shihori Tanabe
Copyright © 2012 Ko Fujimori. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Adipocytes and fat cells play critical roles in the regulation of energy homeostasis. Adipogenesis (adipocyte differentiation) is regulated via a complex process including coordinated changes in hormone sensitivity and gene expression. PPAR is a ligand-dependent transcription factor and important in adipogenesis, as it enhances the expression of numerous adipogenic and lipogenic genes in adipocytes. Prostaglandins (PGs), which are lipid mediators, are associated with the regulation of PPAR function in adipocytes. Prostacyclin promotes the differentiation of adipocyte-precursor cells to adipose cells via activation of the expression of C/EBP and . These proteins are important transcription factors in the activation of the early phase of adipogenesis, and they activate the expression of PPAR, which event precedes the maturation of adipocytes. PGE2 and PGF2α strongly suppress the early phase of adipocyte differentiation by enhancing their own production via receptor-mediated elevation of the expression of cycloxygenase-2, and they also suppress the function of PPAR. In contrast, PGD2 and its non-enzymatic metabolite, -, activate the middle-late phase of adipocyte differentiation through both DP2 receptors and PPAR. This paper focuses on potential roles of PGs as PPAR modulators in adipogenesis and regulators of obesity.
Obesity is a major health concern worldwide  and is associated with the development of a number of pathological disorders such as type 2 diabetes, hypertension, and cardiovascular disease [2–4]. Excess adipose tissue can be the consequence of both an increased number (hyperplasia) and an enlarged size (hypertrophy) of adipose cells. A major role of adipocytes is to store large amounts of triglycerides during periods of energy excess and to mobilize these depots during periods of nutritional deprivation [2–4]. Moreover, adipocytes are highly specialized cells that secrete various adipocytokines, whose release largely reflects the amounts of stored triglyceride [2, 5–8].
The regulation of adipocyte differentiation (adipogenesis) is complex and this process includes alteration of the sensitivity to hormones and the expression of a number of genes in response to various stimuli including lipid mediators. Peroxisome proliferator-activated receptor (PPAR) and CCAAT/enhancer-binding proteins (C/EBPs) are the most important transcription factors involved in the activation of adipogenesis, and they induce the expression of a number of adipogenic and lipogenic genes that participate in the control of adipogenesis [9, 10].
PPARs are members of the nuclear receptor superfamily and play critical roles in the regulation of storage and catabolism of lipids [11, 12]. To date, three types of PPAR subtypes have been identified, that is, PPAR, PPAR, and PPAR [11, 12]. PPARs increase the expression of a variety of genes in various cells through heterodimerization with retinoic acid receptors or retinoid X receptors in a ligand-dependent manner [12–16]. Among them, PPARγ is expressed predominantly in adipose tissue and macrophages, is closely related to the regulation of lipid and glucose metabolisms, and is associated with the control of obesity and related diseases [11, 12]. Until now, many natural and synthetic ligands for PPARγ have been identified [17–19]. 15-Deoxy--prostaglandin (PG) J2 (15d-PGJ2) was the first identified endogenous ligand for PPARγ, and it activates adipogenesis in cultured cells [20, 21]. Moreover, fatty acids such as lauric acid (C12:0) and petroselinic acid (C18:1) of the saturated fatty acids , linolenic acid (C18:3), eicosapentaenoic acid (C20:5), and docosahexaenoic acid (C22:6) of the (n-3) family , arachidonic acid of the ω6 (n-6) family [22, 23], and very-long chain fatty acids  were later identified as other endogenous PPAR ligands that activate PPAR functions. In addition, 9-hydroxy and 13-hydroxy octadecadienoic acids (HODE), the components of oxidized low-density lipoprotein (ox-LDL), were also identified as endogenous ligands for PPARγ [25, 26]. However, whether these natural molecules can function as physiological ligands of PPAR in vivo remains unknown. In addition to natural ligands, many synthetic ligands have been identified. For example, thiazolidinediones (TZDs) such as Troglitazone, Rosiglitazone, Ciglitazone, and Pioglitazone are used for the treatment of type 2 diabetes mellitus; and these ligands affect insulin resistance and glucose homeostasis by activating PPARγ functions [12, 18]. However, these TZDs increase hepatic toxicity and cardiovascular risk. Finally, Troglitazone was withdrawn from the market . It is still unknown whether the toxicities associated with TZDs are derived from the binding with PPAR.
PGs are lipid mediators that play a number of physiological roles in a variety of cells. PGs are synthesized through the following three enzymatic steps (Figure 1). First, arachidonic acid is liberated from the membrane phospholipids by the action of cytosolic phospholipase A2 (cPLA2) . Second, arachidonic acid is converted to PGH2, which is a common precursor of all prostanoids, by either cyclooxygenase- (COX-) 1 or COX-2 . The activity of these enzymes is critical to determine the production rate of PGs. Third, PGH2 is metabolized to various PGs, that is, , , , prostacyclin (PGI2), and thromboxane A2 (TXA2), by the action of specific PG synthases . PGs exert a wide range of actions through their binding to specific PG receptors that belong to the G protein-coupled receptors (GPCRs) gene family . GPCRs span cell membranes via seven transmembrane-spanning segments and are the most important therapeutic targets. In this decade, the functions of PGs in the regulation of adipogenesis have been extensively investigated. Elucidation of the molecular mechanisms underlying adipogenesis may provide strategies for reducing the prevalence of obesity. This paper focuses on the recent advances in our understanding of the function of PGs as modulators of PPARγ in the regulation of adipogenesis.
2. Roles of COXs in Adipocytes
COX consists of two isozymes, COX-1 and COX-2, and is the rate-limiting enzyme in the PG biosynthesis . COX-1 is constitutively expressed in most cells including adipocytes, whereas COX-2 expression is induced by various stimuli  and transiently activated in the early phase of adipogenesis, followed by lowered expression during adipogenesis . There have been a number of reports regarding the contribution of COX isozymes to the regulation of adipocyte differentiation. However, the roles that COX-2 plays during adipogenesis are still controversial.
In cell-based studies, Yan et al. demonstrated that inhibition of COX activities by their selective inhibitors, for example, SC-560 for COX-1, and NS-398 and Celecoxib for COX-2, enhances adipocyte differentiation via an increase in the mRNA levels of PPARγ and C/EBPα. Thus, both COX-1 and COX-2 participate in the regulation of adipogenesis . Moreover, in 3T3-L1 cells stably expressing COX-2 in the antisense direction, lipid accumulation is enhanced during adipogenesis with elevated expression of adipogenic genes such as PPARγ and C/EBPα. In addition, this enhancement of lipid accumulation in antisense COX-2-expressing cells can be reversed by cotreatment with either antiadipogenic PGE2 or PGF2α .
In contrast, when 3T3-L1 cells are pretreated before the initiation of adipocyte differentiation or treated during the clonal expansion phase with SC-58236, a selective COX-2 inhibitor, and then caused to differentiate into adipocytes, lipid accumulation is reduced along with repressed expression of the adipogenic fatty acid-binding protein 4 (FABP4, also called aP2) gene . In contrast, a selective COX-1 inhibitor, SC-58560 does not have any effect on adipogenesis. Additionally, when 3T3-L1 cells are caused to differentiate into adipocyte in a medium containing each of two selective COX-1 and COX-2 inhibitors that are added after the clonal expansion phase, adipogenesis is not affected. Thus, inhibition of COX-2 activity suppresses adipocyte differentiation by repressing the clonal expansion phase .
In in vivo studies, overexpression of COX-2 in white adipose tissue (WAT) increases de novo recruitment of brown adipose tissue (BAT) and energy expenditure, while suppressing the high fat diet-induced gain in body weight . Also, Ghoshal et al. reported that in COX-2 gene-knock-out mice, their total body weight is significantly lower than that of wild-type mice, along with reduced expression of adipogenic genes such as those of PPARγ and lipoprotein lipase . In addition, PGD2 and 15d-PGJ2 levels in cells prepared from adipose tissues of COX-2 gene-knock-out mice and placed in primary culture are reduced as compared with those in wild-type mice . Thus, further studies are needed to elucidate the precise functions of COXs in the regulation of adipogenesis.
3. Repression of the Early Phase of Adipogenesis by PGF
is synthesized by a variety of PGF synthase (PGFS) activity-carrying enzymes , for example, aldoketo reductase (AKR) 1B3 , AKR1B7 , and prostamide/PGFS  in mice. In humans, AKR1C3 acts as a PGFS in adipocytes and is associated with the suppression of adipogenesis through inhibition of PPARγ function . Although PGFS has never been identified in adipocytes, we and another group identified AKR1B3  and AKR1B7  as being PGFSs in adipocytes.
AKR1B3-produced is detected in preadipocytes and its level is enhanced with a peak at 3 h after the initiation of adipogenesis and then decreases , indicating that suppresses an early phase of adipogenesis. Fluprostenol, an FP receptor agonist, clearly reduces the expression of PPAR and its target genes [31, 50]. Moreover, this Fluprostenol-mediated suppression of the gene expression is cleared by cotreatment with AL8810, an FP receptor antagonist, indicating that inhibits adipocyte differentiation of 3T3-L1 cells by acting through an FP receptor.
AKR1B7 gene-knock-out mice display excessive adiposity resulting from adipocyte hyperplasia/hypertrophy and exhibit high sensitivity to diet-induced obesity. Treatment of 3T3-L1 cells or AKR1B7 gene-knock-out mice with Cloprostenol, an FP receptor agonist, decreases adipocyte size and inhibits the expression of lipogenic genes .
The precise molecular mechanism of -mediated suppression of adipogenesis has been investigated. represses the function of PPAR by causing its phosphorylation via FP receptors . In addition, Fluprostenol enhances the expression of COX-2 via activation of the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 pathway. Moreover, promoter-luciferase and chromatin immunoprecipitation assays demonstrated that -derived COX-2 expression is activated by the binding of cAMP-responsive element binding protein (CREB) to the promoter region of the COX-2 gene in 3T3-L1 cells . Thus, the MEK/ERK-CREB cascade forms a positive feedback loop, one that probably plays a critical role in the suppression of the early phase of adipogenesis by elevating the de novo production of antiadipogenic .
4. Suppression of the Early Phase of Adipogenesis by PGE2
PGE2 is also known to suppress adipogenesis through suppression of PPAR function. and an EP4 agonist, AE1-329, increase the intracellular cAMP levels in preadipocytes in a dose-dependent manner . Moreover, AE1-329 decreases the expression of adipogenic genes such as PPAR and C/EBP . The inhibitory effect of , but not that of Fluprostenol, is reversed by the addition of an EP4 antagonist, AE3-208 , indicating that PGE2 suppresses adipogenesis through the EP4 receptor. Although the functions of PGE2 and the expression of the functions of PGE2 and the expression of PGESs have been investigated in adipocytes [27, 52, 53], the PGE2-producing enzyme in adipocytes has never been identified. To date, three major PGESs have been identified [54, 55]. Microsomal PGES-1 (mPGES-1) is a member of the membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG) protein family  and produces PGE2 in response to various stimuli . Microsomal PGES-2 (mPGES-2) has also been identified and its expression is high in the heart and brain . Cytosolic PGES (cPGES) is constitutively and ubiquitously expressed in various cells .
PGE2 production is detected in preadipocytes and increases during the early phase of adipogenesis with a peak at 3 h after the initiation of adipogenesis; and mPGES-1 is expressed in these cells, with its mRNA and protein levels being consistently detected during adipogenesis. Finally, we found that mPGES-1 is responsible for the production of PGE2 in adipocytes . This result is consistent with results showing that treatment of mouse embryonic fibroblast (MEF) cells with for the first two days of adipocyte differentiation is enough to suppress adipocyte differentiation, with reduced expression of the PPAR2 gene and reduced accumulation of intracellular lipids .
In wild-type mouse MEF cells, inhibition of endogenous PG synthesis by indomethacin enhances adipocyte differentiation, and this enhancement is reversed by the addition of . In MEF cells prepared from EP4 receptor gene-knock-out mice, adipocyte differentiation is elevated, and no more enhancement of adipocyte differentiation is observed following treatment with indomethacin. Thus, -EP4 receptor signaling suppresses the early phase of adipocyte differentiation in MEF cells .
5. Synergistic Suppression of Early Phase of Adipogenesis by PGF and PGE2
Both and suppress the early phase of adipogenesis, and so we investigated the synergistic regulation of these PGs in 3T3-L1 cells. The increased production of and in the early phase of adipogenesis is a consequence of the elevated expression of the COX-2 gene . forms a positive feedback loop that coordinately suppresses the early phase of adipogenesis through the increased production of antiadipogenic and , both of which inhibit PPAR function. In addition, also enhances the production of and itself through the elevation of the expression of the COX-2 gene in an EP4 receptor-mediated fashion. Moreover, when the cells are caused to differentiate into adipocytes in medium containing both and , the expression of the adipogenic genes is decreased to a greater extent than when the cells are cultured in a medium containing either of them. Thus, PGE2 and PGF2α synergistically suppress the early phase of adipogenesis through a self-amplifying loop, triggered by -FP receptor and PGE2-EP4 receptor couplings and activation of the COX-2 gene expression in 3T3-L1 cells .
However, Inazumi et al. demonstrated that the differentiation of MEF cells prepared from FP receptor gene-knock-out mice is almost the same as that in these cells from wild-type mice and still shows sensitivity to indomethacin, indicating that FP receptor-mediated suppression is not directly associated with the regulation of adipocyte differentiation in MEF cells . Therefore, the regulation of suppression of adipogenesis by and might occur in a cell-type-dependent manner.
6. Acceleration of Adipocyte Differentiation by PGD2 and Its Metabolites
PGD2 acts as an allergic and inflammatory mediators and is produced in a variety of cells such as mast cells, macrophages, and adipose cells [62, 63]. PGD2 is produced from PGH2 by the action of PGD synthases (PGDSs), enzymes that catalyze the isomerization of the 9,11-endoperoxide group of PGH2 to PGD2. Two distinct types of PGDSs have been identified. One is hematopoietic PGDS (H-PGDS), which is abundantly expressed in mast cells and Th2 cells . The other is L-PGDS, which is detected abundantly in the brain, male genital organs, and heart [62, 63].
PGD2 has been considered a candidate for a molecule that acts as an endogenous inducer of adipogenesis, basically because 15d-PGJ2, one of its metabolites, has been identified as a ligand for PPARγ and activates adipogenesis in vitro [20, 21]. PGD2 is nonenzymatically metabolized to PGs of the J series, that is, PGJ2, Δ12-PGJ2, and 15d-PGJ2. However, the concentrations of 15d-PGJ2 required for the activation of PPARγ reported in most of the literature are much higher (2.5–100 mol/L) than those of conventional PGs (pmol/L range); and 15d-PGJ2 is present in vivo at a low level that is insufficient for activation of adipocyte differentiation , whose finding is consistent with our current results indicating that 15d-PGJ2 is not detectable in adipocytes . Recently, we identified Δ12-PGJ2 as being the dominant PGD2 metabolite in differentiated adipocytes , in good agreement with recent results showing that Δ12-PGJ2 is produced in adipocytes and activates the expression of adipogenic genes in 3T3-L1 cells .
PGD2 is synthesized by the action of L-PGDS in adipocytes . However, another PGDS, H-PGDS may not be involved in the production of PGD2 in adipocytes, because the expression level of H-PGDS is very low during adipogenesis. Although the function of PGD2 or L-PGDS in vitro has been extensively investigated, the in vivo function is still controversial. Ragolia et al. reported that adipose size is increased in L-PGDS gene-knock-out mice under normal and high-fat diet feeding. Moreover, L-PGDS gene-knock-out mice become glucose intolerant and insulinresistant. Also the serum adiponectin level is decreased in such mice . Adipocytes isolated from L-PGDS gene-knock-out mice are significantly less sensitive to insulin-stimulated glucose transport. Thus, L-PGDS is an important mediator of muscle and adipose glucose transport which is modulated by glycemic conditions and plays a significant role in the glucose intolerance associated with type 2 diabetes . Furthermore, Tanaka et al. showed that L-PGDS gene-knock-out mice have a significantly increased body weight when fed high-fat diet and the size of adipocytes in the subcutaneous and visceral fat tissues is significantly enlarged .
In contrast, Fujitani et al. demonstrated that transgenic mice overexpressing human H-PGDS, which produce plenty of PGD2 in every tissue including adipose, become obese under high-fat diet feeding but that obesity is not observed under normal diet feeding . Serum leptin, insulin, and adiponectin levels are increased in these PGD2-overproducing mice. Moreover, their triglyceride level is decreased by about 50% as compared with that in WT mice. Moreover, the PGD2-overproducing mice show increased insulin sensitivity . Furthermore, the epididymal adipose tissue mass of COX-2 gene-knock-out mice is decreased. PGD2 and the levels of PGD2 metabolites are also decreased in the adipose tissue of these mice. Thus, reduced adiposity in COX-2 gene-knock-out mice results from the inhibition of the production of PGD2 and its metabolites required for PPARγ activation . This discrepancy may be derived from a variety of physiological functions of PGD2 in the body. Therefore, the adipocyte-specific function of PGD2 and/or L-PGDS in the regulation of obesity should be further clarified.
7. Activation of Adipogenesis in Adipose-Precursor Cells by PGI2
PGI2 activates the protein kinase A (PKA) pathway by binding to its IP receptor and enhances the differentiation of adipose precursor cells [72, 73].The activation of IP receptors upregulates the expression of C/EBP and C/EBP, both of which are critical for the progression of the early phase of adipogenesis and directly activate the expression of the PPARγ and C/EBPα genes for maturation of adipocytes [9, 10]. Moreover, IP receptor gene-knock-out mice fed a high-fat diet do not show any changes in body weight, fat mass, or adipose size [74, 75]. Therefore, PGI2 activates the progression of adipogenesis in the adipose precursor cells through the enhancement of the expression C/EBP and C/EBP via the cAMP-PKA pathway.
PGs are involved in the regulation of adipogenesis and act as modulators of PPARγ functions. The regulation of adipogenesis by PGs is very complex, because PGs regulate adipogenesis both positively and negatively. In the early phase of adipogenesis, PGF2α and PGE2 suppress the progression of adipogenesis, and their receptor-mediated mechanisms leading to suppressed PPARγ function have been well elucidated. In contrast, PGD2 and its metabolites activate the middle-late phase of adipogenesis (Figure 2). In addition, recently we found that PGD2 and its metabolite Δ12-PGJ2 accelerate adipogenesis by acting through DP2 (CRTH2; chemoattractant receptor homologous molecule of Th2 cells) receptors and PPARγ, thus, indicating that when elucidating the function of a given PG, the roles of not only it but also those of its metabolites should be considered.
All PGs function through their specific G protein-coupled receptors and PPARγ. Although their receptor agonists and antagonists are functional in the cultured adipocytes (in vitro), in vivo studies do not show clear effects of PGs in the regulation of obesity. Moreover, PG receptor gene-knock-out mice are not affected like the cells observed in in vitro studies. The explanation of the problems is quite difficult. As PGs have a variety of physiological functions, studies using gene-knock-out mice might not be appropriate to elucidate the functions of PGs in obesity. The precise in vivo functions of PGs especially those of 15d-PGJ2 required further clarification. Tissue- (cell-)specific gene-knock-out mice might be a powerful tool to identify the in vivo function of PGs. Understanding of the mechanisms of PG-mediated regulation of adipogenesis may lead to a novel therapeutic strategy for the treatment of obesity.
The author’s studies cited in this paper were supported in part by Grants from the programs of theGrant-in-Aid for Scientific Research and Scientific Research on Innovative Areas of the Ministry of Education, Culture, Sports, Science and Technology of Japan and Technology of Japan (MEXT), and Research for Promoting Technological Seeds of Japan Science and Technology Agency (JST) and by Grants from the Suzuken Memorial Foundation, the Sumitomo Foundation, the Japanese Biochemical Society, the Japan Foundation for Applied Enzymology, the Takeda Science Foundation, the Naito Foundation, the Research Foundation for Pharmaceutical Sciences, and the Daiwa Securities Health Foundation.
- J. M. Friedman, “Modern science versus the stigma of obesity,” Nature Medicine, vol. 10, no. 6, pp. 563–569, 2004.
- A. D. Attie and P. E. Scherer, “Adipocyte metabolism and obesity,” Journal of Lipid Research, vol. 50, pp. S395–S399, 2009.
- M. A. Cornier, D. Dabelea, T. L. Hernandez et al., “The metabolic syndrome,” Endocrine Reviews, vol. 29, no. 7, pp. 777–822, 2008.
- X. Pi-Sunyer, “The medical risks of obesity,” Postgraduate Medicine, vol. 121, no. 6, pp. 21–33, 2009.
- S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as an endocrine organ,” Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 129–139, 2010.
- N. Rasouli and P. A. Kern, “Adipocytokines and the metabolic complications of obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 11, pp. s64–s73, 2008.
- B. Antuna-Puente, B. Feve, S. Fellahi, and J. P. Bastard, “Adipokines: the missing link between insulin resistance and obesity,” Diabetes and Metabolism, vol. 34, no. 1, pp. 2–11, 2008.
- Y. Matsuzawa, “Adiponectin: a key player in obesity related disorders,” Current Pharmaceutical Design, vol. 16, no. 17, pp. 1896–1901, 2010.
- M. I. Lefterova and M. A. Lazar, “New developments in adipogenesis,” Trends in Endocrinology and Metabolism, vol. 20, no. 3, pp. 107–114, 2009.
- E. Rosen, J. Eguchi, and Z. Xu, “Transcriptional targets in adipocyte biology,” Expert Opinion on Therapeutic Targets, vol. 13, no. 8, pp. 975–986, 2009.
- S. I. Anghel and W. Wahli, “Fat poetry: a kingdom for PPARγ,” Cell Research, vol. 17, no. 6, pp. 486–511, 2007.
- C. Christodoulides and A. Vidal-Puig, “PPARs and adipocyte function,” Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 61–68, 2010.
- U. A. White and J. M. Stephens, “Transcriptional factors that promote formation of white adipose tissue,” Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 10–14, 2010.
- R. Siersbæk, R. Nielsen, and S. Mandrup, “PPARγ in adipocyte differentiation and metabolism—novel insights from genome-wide studies,” FEBS Letters, vol. 584, no. 15, pp. 3242–3249, 2010.
- P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008.
- A. M. Sharma and B. Staels, “Review: peroxisome proliferator-activated receptor γ and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 386–395, 2007.
- Y. Tabe, M. Konopleva, M. Andreeff, and A. Ohsaka, “Effects of PPARγ ligands on leukemia,” PPAR Research, vol. 2012, Article ID 483656, 8 pages, 2012.
- B. Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPARγ agonists: time for a reassessment,” Trends in Endocrinology and Metabolism, vol. 23, no. 5, pp. 205–215, 2012.
- M. Penumetcha and N. Santanam, “Nutraceuticals as ligands of PPARγ,” PPAR Research, vol. 2012, Article ID 858352, 7 pages, 2012.
- B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy--prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995.
- S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995.
- S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997.
- G. Krey, O. Braissant, F. L'Horset et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997.
- T. Kobayashi and K. Fujimori, “Very long chain-fatty acids enhance adipogenesis through co-regulation of Elovl3 and PPARγ in 3T3-L1 cells,” American Journal of Physiology, Endocrinology and Metabolism, vol. 302, no. 12, pp. E1461–E1471, 2012.
- L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998.
- P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998.
- M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters, “The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR),” Toxicological Sciences, vol. 90, no. 2, pp. 269–295, 2006.
- M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: from cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011.
- W. L. Smith, Y. Urade, and P. J. Jakobsson, “Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis,” Chemical Reviews, vol. 111, no. 10, pp. 5821–5865, 2011.
- S. Narumiya and T. Furuyashiki, “Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years,” FASEB Journal, vol. 25, no. 3, pp. 813–818, 2011.
- K. Fujimori, T. Ueno, N. Nagata et al., “Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin synthase,” Journal of Biological Chemistry, vol. 285, no. 12, pp. 8880–8886, 2010.
- H. Yan, A. Kermouni, M. Abdel-Hafez, and D. C. W. Lau, “Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells,” Journal of Lipid Research, vol. 44, no. 2, pp. 424–429, 2003.
- X. Chu, K. Nishimura, M. Jisaka, T. Nagaya, F. Shono, and K. Yokota, “Up-regulation of adipogenesis in adipocytes expressing stably cyclooxygenase-2 in the antisense direction,” Prostaglandins and Other Lipid Mediators, vol. 91, no. 1-2, pp. 1–9, 2010.
- L. Fajas, S. Miard, M. R. Briggs, and J. Auwerx, “Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase,” Journal of Lipid Research, vol. 44, no. 9, pp. 1652–1659, 2003.
- A. Vegiopoulos, K. Müller-Decker, D. Strzoda et al., “Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes,” Science, vol. 328, no. 5982, pp. 1158–1161, 2010.
- S. Ghoshal, D. B. Trivedi, G. A. Graf, and C. D. Loftin, “Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice,” Journal of Biological Chemistry, vol. 286, no. 1, pp. 889–898, 2011.
- D. A. Casimir, C. W. Miller, and J. M. Ntambi, “Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells,” Differentiation, vol. 60, no. 4, pp. 203–210, 1996.
- L. Liu and N. A. Clipstone, “Prostaglandin inhibits adipocyte differentiation via a Gαq-calcium-calcineurin-dependent signaling pathway,” Journal of Cellular Biochemistry, vol. 100, no. 1, pp. 161–173, 2007.
- C. W. Miller, D. A. Casimir, and J. M. Ntambi, “The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin ,” Endocrinology, vol. 137, no. 12, pp. 5641–5650, 1996.
- G. Serrero and N. M. Lepak, “Prostaglandin receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium,” Biochemical and Biophysical Research Communications, vol. 233, no. 1, pp. 200–202, 1997.
- M. J. Reginato, S. L. Krakow, S. T. Bailey, and M. A. Lazar, “Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ,” Journal of Biological Chemistry, vol. 273, no. 4, pp. 1855–1858, 1998.
- H. Tsuboi, Y. Sugimoto, T. Kainoh, and A. Ichikawa, “Prostanoid EP4 receptor is involved in suppression of 3T3-L1 adipocyte differentiation,” Biochemical and Biophysical Research Communications, vol. 322, no. 3, pp. 1066–1072, 2004.
- T. Inazumi, N. Shirata, K. Morimoto, H. Takano, E. Segi-Nishida, and Y. Sugimoto, “Prostaglandin E2-EP4 signaling suppresses adipocyte differentiation in mouse embryonic fibroblasts via an autocrine mechanism,” Journal of Lipid Research, vol. 52, no. 8, pp. 1500–1508, 2011.
- K. Watanabe, “Recent reports about enzymes related to the synthesis of prostaglandin (PG) F2 (PG and 9, 11-PGF2,” Journal of Biochemistry, vol. 150, no. 6, pp. 593–596, 2011.
- Z. Kabututu, M. Manin, J. C. Pointud et al., “Prostaglandin synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7,” Journal of Biochemistry, vol. 145, no. 2, pp. 161–168, 2009.
- J. Tirard, J. Gout, A. M. Lefrançois-Martinez, A. Martinez, M. Begeot, and D. Naville, “A novel inhibitory protein in adipose tissue, the aldo-keto reductase AKR1B7: its role in adipogenesis,” Endocrinology, vol. 148, no. 5, pp. 1996–2005, 2007.
- H. Moriuchi, N. Koda, E. Okuda-Ashitaka et al., “Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily,” Journal of Biological Chemistry, vol. 283, no. 2, pp. 792–801, 2008.
- M. C. Byrns, Y. Jin, and T. M. Penning, “Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights,” Journal of Steroid Biochemistry and Molecular Biology, vol. 125, no. 1-2, pp. 95–104, 2011.
- F. E. Volat, J. C. Pointud, E. Pastel et al., “Depressed levels of prostaglandin in mice lacking akr1b7 increase basal adiposity and predispose to diet-Induced obesity,” Diabetes, vol. 61, no. 11, pp. 2796–2806, 2012.
- T. Ueno and K. Fujimori, “Novel suppression mechanism operating in early phase of adipogenesis by positive feedback loop for enhancement of cyclooxygenase-2 expression through prostaglandin receptor mediated activation of MEK/ERK-CREB cascade,” FEBS Journal, vol. 278, no. 16, pp. 2901–2912, 2011.
- Y. Sugimoto, H. Tsuboi, Y. Okuno et al., “Microarray evaluation of EP4 receptor-mediated prostaglandin E2 suppression of 3T3-L1 adipocyte differentiation,” Biochemical and Biophysical Research Communications, vol. 322, no. 3, pp. 911–917, 2004.
- Y. Xie, X. Kang, W. E. Ackerman et al., “Differentiation-dependent regulation of the cyclooxygenase cascade during adipogenesis suggests a complex role for prostaglandins,” Diabetes, Obesity and Metabolism, vol. 8, no. 1, pp. 83–93, 2006.
- P. O. Hétu and D. Riendeau, “Down-regulation of microsomal prostaglandin E2 synthase-1 in adipose tissue by high-fat feeding,” Obesity, vol. 15, no. 1, pp. 60–68, 2007.
- S. Hara, D. Kamei, Y. Sasaki, A. Tanemoto, Y. Nakatani, and M. Murakami, “Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models,” Biochimie, vol. 92, no. 6, pp. 651–659, 2010.
- D. F. Legler, M. Bruckner, E. Uetz-von Allmen, and P. Krause, “Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 2, pp. 198–201, 2010.
- P. J. Jakobsson, S. Thorén, R. Morgenstern, and B. Samuelsson, “Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7220–7225, 1999.
- B. Samuelsson, R. Morgenstern, and P. J. Jakobsson, “Membrane prostaglandin E synthase-1: a novel therapeutic target,” Pharmacological Reviews, vol. 59, no. 3, pp. 207–224, 2007.
- N. Tanikawa, Y. Ohmiya, H. Ohkubo et al., “Identification and characterization of a novel type of membrane-associated prostaglandin E synthase,” Biochemical and Biophysical Research Communications, vol. 291, no. 4, pp. 884–889, 2002.
- T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, and I. Kudo, “Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis,” Journal of Biological Chemistry, vol. 275, no. 42, pp. 32775–32782, 2000.
- K. Fujimori, T. Maruyama, S. Kamauchi, and Y. Urade, “Activation of adipogenesis by lipocalin-type prostaglandin D synthase-generated -PGJ2 acting through PPARγ-dependent and independent pathways,” Gene, vol. 505, no. 1, pp. 46–52, 2012.
- K. Fujimori, M. Yano, and T. Ueno, “Synergistic suppression of early phase of adipogenesis by microsomal PGE synthase-1 (PTGES1)-produced PGE2 and aldo-keto reductase 1B3-produced PG,” PloS ONE, vol. 7, no. 9, Article ID e44698, 2012.
- Y. Urade and O. Hayaishi, “Prostaglandin D synthase: structure and function,” Vitamins and Hormones, vol. 58, pp. 89–120, 2000.
- Y. Urade and O. Hayaishi, “Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase,” Biochimica et Biophysica Acta, vol. 1482, no. 1-2, pp. 259–271, 2000.
- Y. Kanaoka and Y. Urade, “Hematopoietic prostaglandin D synthase,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 69, no. 2-3, pp. 163–167, 2003.
- L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “Biosynthesis of 15-deoxy--PGJ2 and the ligation of PPARγ,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 945–955, 2003.
- M. S. Hossain, A. A. Chowdhury, M. S. Rahman et al., “Development of enzyme-linked immunosorbent assay for - prostaglandin J2 and its application to the measurement of the endogenous product generated by cultured adipocytes during the maturation phase,” Prostaglandins and Other Lipid Mediators, vol. 94, no. 3-4, pp. 73–80, 2011.
- K. Fujimori, K. Aritake, and Y. Urade, “A novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c,” Journal of Biological Chemistry, vol. 282, no. 25, pp. 18458–18466, 2007.
- L. Ragolia, T. Palaia, C. E. Hall, J. K. Maesaka, N. Eguchi, and Y. Urade, “Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice,” Journal of Biological Chemistry, vol. 280, no. 33, pp. 29946–29955, 2005.
- L. Ragolia, C. E. Hall, and T. Palaia, “Lipocalin-type prostaglandin D2 synthase stimulates glucose transport via enhanced GLUT4 translocation,” Prostaglandins and Other Lipid Mediators, vol. 87, no. 1–4, pp. 34–41, 2008.
- R. Tanaka, Y. Miwa, K. Mou et al., “Knockout of the l-pgds gene aggravates obesity and atherosclerosis in mice,” Biochemical and Biophysical Research Communications, vol. 378, no. 4, pp. 851–856, 2009.
- Y. Fujitani, K. Aritake, Y. Kanaoka et al., “Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D2 in vivo,” FEBS Journal, vol. 277, no. 6, pp. 1410–1419, 2010.
- G. Vassaux, D. Gaillard, G. Ailhaud, and R. Negrel, “Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca2+-elevating agent,” Journal of Biological Chemistry, vol. 267, no. 16, pp. 11092–11097, 1992.
- G. Vassaux, D. Gaillard, C. Darimont, G. Ailhaud, and R. Negrel, “Differential response of preadipocytes and adipocytes to prostacyclin and prostaglandin E2: physiological implications,” Endocrinology, vol. 131, no. 5, pp. 2393–2398, 1992.
- J. Aubert, P. Saint-Marc, N. Belmonte, C. Dani, R. Négrel, and G. Ailhaud, “Prostacyclin IP receptor up-regulates the early expression of C/EBPβ and C/EBPδ in preadipose cells,” Molecular and Cellular Endocrinology, vol. 160, no. 1-2, pp. 149–156, 2000.
- F. Massiera, P. Saint-Marc, J. Seydoux et al., “Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern?” Journal of Lipid Research, vol. 44, no. 2, pp. 271–279, 2003.